Therapeutic Specialties Archives | 第 11 页，共 27 页 | Certara

Publication

Prediction of Olanzapine Exposure in Individual Patients Using Physiologically-based Pharmacokinetic Modeling and Simulation

Danielle Pillsbury2017 年 11 月 30 日

Publication

Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

Danielle Pillsbury2017 年 11 月 1 日

Publication

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach

Danielle Pillsbury2017 年 9 月 15 日

Publication

Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types

Danielle Pillsbury2017 年 8 月 1 日

Publication

Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

Danielle Pillsbury2017 年 7 月 15 日

Poster

Predicting Diclofenac Systemic and Synovial Fluid Concentrations After Dermal Application Using the Multi-phase Multi-layer MechDermA PBPK Model

Danielle Pillsbury2017 年 6 月 6 日

Publication

Time Dependent Pharmacokinetics of Pembrolizumab in Patients with Solid Tumor and Its Correlation with Best Overall Response

Danielle Pillsbury2017 年 6 月 1 日

On-Demand Webinar

Obeticholic Acid—From PK Model to Drug Label

Watch this webinar with Jeffrey Edwards to learn how he used physiologic pharmacokinetic modeling to…

Danielle Pillsbury2017 年 6 月 1 日

Publication

Evaluation of Dosing Strategy for Pembrolizumab for Oncology Indications

Danielle Pillsbury2017 年 5 月 1 日

Publication

Effect of Disease-related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats

Danielle Pillsbury2017 年 5 月 1 日

© 2025 Certara. 保留所有权力。 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software